Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1989-4-5
pubmed:abstractText
Attempts to improve the selectivity of anti-cancer agents by conjugating them to antibodies directed at tumour associated antigens have demonstrated tumour localisation but only limited therapeutic success. We report here the advantage of a 2-stage approach in which the first component combines the selective delivery of antibody with a capability to generate a cytotoxic agent from a second subsequently administered component. A bacterial enzyme, carboxypeptidase G2 (CPG2) was conjugated with F(ab')2 fragment of a monoclonal antibody directed at beta subunit of human chorionic gonadotrophin (beta-hCG) and injected into nude mice bearing hCG producing CC3 xenografts of human choriocarcinoma. Time was allowed for the conjugate to localise at tumour sites and clear from blood before injecting para-N-bis (2-chloroethyl) aminobenzoylglutamic acid. Cleavage of the glutamic acid moiety from this molecule by CPG2 released a benzoic acid mustard. Growth of the tumour which is resistant to conventional chemotherapy was markedly depressed by a single course of treatment. This demonstrates for the first time the potential of an antibody directed enzyme to activate an alkylating agent and to eradicate an established human cancer xenograft.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-14046614, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-14473560, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-2432984, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-2447021, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-2991647, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-3426915, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-3704478, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-3838935, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-3935755, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-3955497, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-3964540, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-6168276, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-6184153, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-6193072, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-6358192, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-6538552, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-7122253, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-7471071, http://linkedlifedata.com/resource/pubmed/commentcorrection/3265633-989623
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
58
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
700-3
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
A cytotoxic agent can be generated selectively at cancer sites.
pubmed:affiliation
Department of Medical Oncology, Charing Cross Hospital, London, UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't